Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
View Patent ↗Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.
1. A method of administering a therapeutic dose of a reversibly inactivated acidified mammalian serine protease composition to a human or animal having a thrombotic occlusion, comprising the steps of:
a) identifying a human or animal having a thrombotic occlusion; and
b) administering parenterally to the human or animal a therapeutic dose of a pharmaceutically acceptable reversibly inactivate acidified mammalian serine protease composition substantially free o plasminogen activator, wherein the therapeutic dose is delivered into or proximally to the thrombotic occlusion;
wherein the mammalian serine protease composition comprises a low buffering capacity buffer and has a pH less than about 4.0,
and wherein the composition is a pharmaceutically acceptable solution that can be raised to a physiological pH by adding no more than about 5 volumes of serum to the solution relative to the volume of solution.
2. The method of claim 1 , further comprising the step:
c) allowing the administered mammalian serine protease composition to interact with the thrombotic occlusion.
3. The method of claim 2 , further comprising the steps:
d) monitoring the level of vascular flow of the human or animal; and
e) repeating steps (a)-(d) until a pre-selected level of vascular flow is attained.
4. The method of claim 1 , wherein the thrombotic occlusion is a vascular occlusion selected from a coronary thrombosis, deep venous thrombosis, peripheral thrombosis, embolic thrombosis, hepatic vein thrombosis, marasmic thrombosis, sinus thrombosis, venous thrombosis, an arterial thrombosis, an occluded arterio-venal shunt, or an occluded catheter device.
5. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition is lyophilized, and wherein the method further comprises adding a pharmaceutically acceptable carrier to the lyophilized mammalian serine protease composition before administration to the human or animal.
6. The method of claim 1 , wherein the reversibly inactivated acidified mammalian seine protease composition comprises Glu-plasmin, Lys-plasmin, mini-plasmin, micro-plasmin, or a truncated variant thereof.
7. The method of claim 1 , wherein the reversibly inactivated acidified mammalian seine protease composition further comprises an anti-thrombotic agent.
8. The method of claim 1 , wherein the low buffering capacity buffer comprises water and at least one pharmaceutically acceptable acid, wherein the acid is an organic acid selected from a carboxylic acid, an oligopeptide, an amino acid, or inorganic acid.
9. The method of claim 8 , wherein the pharmaceutically acceptable acid is selected from formic acid, acetic acid, citric acid, glycine, isoleucine, serine, threonine, glutamine, aspartic acid, valine and alanine.
10. The method of claim 8 , wherein the pharmaceutically acceptable acid is acetic acid or citric acid.
11. The method of claim 8 , wherein the pharmaceutically acceptable acid is acetic acid.
12. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition has a pH of between about 2.5 and about 4.0.
13. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition has a pH of between about 3.0 and about 4.0.
14. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition has a pH of between about 3.1 and about 3.5.
15. The method of claim 7 , wherein the mammalian serine protease is in a concentration range of between about 0.01 mg/ml to about 50 mg/ml.
16. The method of claim 7 , wherein the mammalian serine protease is in a concentration range of between about 0.1 mg/ml to about 10 mg/ml.
17. The method of claim 8 , wherein the acid is in a concentration range of between about 1 mM to about 500 mM.
18. The method of claim 8 , wherein the acid is in a concentration range of between about 1 mM and 50 mM.
19. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition further comprises a stabilizing agent.
20. The method of claim 19 , wherein the stabilizing agent is a pharmaceutically acceptable carbohydrate selected from glucose, maltose, mannitol, sorbitol, sucrose, lactose or trehalose.
21. The method of claim 20 , wherein the carbohydrate has a concentration in a range of about 0.2% w/v to about 20% w/v.
22. The method of claim 20 , wherein the carbohydrate is glucose and the concentration thereof is about 20%.
23. The method of claim 20 , wherein the stabilizing agent is selected from glucosamine, niacinamide and thiamine.
24. The method of claim 20 , wherein the stabilizing agent has a concentration in the range of about 0.01M to about 0.1M.
25. The method of claim 1 , wherein the therapeutic dose of the reversibly inactivated acidified mammalian serine protease composition is in a range of between about 0.1 mg plasmin/kg body weight and 10.0 mg plasmin/kg body weight.
26. The method of claim 1 , wherein the therapeutic dose of the reversibly inactivated acidified mammalian serine protease composition is in a range of between about 0.2 mg plasmin/kg body weight and 4.0 mg plasmin/kg body weight.
27. The method of claim 1 , wherein the therapeutic dose of the reversibly inactivated acidified mammalian serine protease composition is in a range of between about 1.0 mg plasmin/kg body weight and 2.0 mg plasmin/kg body weight.
28. The method of claim 1 , wherein the reversibly inactivated acidified mammalian serine protease composition is administered by a catheter device.
29. The method of claim 28 , wherein the catheter device is directed to a vascular occlusion.
30. The method of claim 29 , wherein the catheter device delivers the reversibly inactivated acidified mammalian serine protease composition proximal to, or into, a thrombotic occlusion.
31. The method of claim 29 , wherein the catheter device enters the thrombotic occlusion and the catheter delivers the reversibly inactivated acidified mammalian serine protease composition directly into the thrombotic occlusion.
32. The method of claim 1 , wherein the solution can be raised to physiological pH by adding no more than about 1 volume of serum to the solution relative to the volume of solution.
33. The method of claim 1 , wherein the solution can be raised to physiological pH by adding no more than about 0.7 volumes of serum to the solution relative to the volume of solution.
34. The method of claim 1 , wherein the solution can be raised to physiological pH by adding no more than about 0.3 volumes of serum to the solution relative to the volume of solution.
35. The method of claim 1 , wherein the solution can be raised to physiological pH by adding no more than about 0.1 volumes of serum to the solution relative to the volume of solution.